ENG and neoplasm: The efficacy of CD105 CAR-T in the treatment of solid tumors still requires further optimization and explority use on other tumor types as an extension of this work before clinical trials, such as injection methodology and the dosage (CAR-T cell number) of administration, which required validatation by using some additional models.